Tumour Suppressor Function of RNase L in A Mouse Model by Liu, Wendy et al.
Cleveland State University
EngagedScholarship@CSU
Chemistry Faculty Publications Chemistry Department
1-1-2007
Tumour Suppressor Function of RNase L in A
Mouse Model
Wendy Liu
Case Western Reserve University
Shu Ling Liang
Johns Hopkins University
Hongli Liu
Cleveland State University
Robert Silverman
Cleveland State University, R.SILVERMAN33@csuohio.edu
Aimin Zhou
Cleveland State University, A.ZHOU@csuohio.edu
Follow this and additional works at: https://engagedscholarship.csuohio.edu/scichem_facpub
Part of the Chemistry Commons
How does access to this work benefit you? Let us know!
This Article is brought to you for free and open access by the Chemistry Department at EngagedScholarship@CSU. It has been accepted for inclusion
in Chemistry Faculty Publications by an authorized administrator of EngagedScholarship@CSU. For more information, please contact
library.es@csuohio.edu.
Recommended Citation
Liu, Wendy; Liang, Shu Ling; Liu, Hongli; Silverman, Robert; and Zhou, Aimin, "Tumour Suppressor Function of RNase L in A
Mouse Model" (2007). Chemistry Faculty Publications. 422.
https://engagedscholarship.csuohio.edu/scichem_facpub/422
202 
Tumour suppressor function of RNase L in a mouse model 
Wendy Liu , Shu-Ling Liang , Hongli Liu , Robert Silverman , Aimin Zhou 
Introduction 
Interferons (IFNs) are a family of cytokines participating in in 
nate immunity against a wide range of viruses and other 
microbial pathogens.1 IFNs also have anti tumour activities 
due to their anti proliferative, immunoregulatory and apopto 
tic properties.2 The effects of IFNs are largely mediated 
through proteins encoded by IFN stimulated genes (ISGs). 
One well studied ISG is RNase L, which is one of the key en 
zymes in the IFN induced 2 SA system. 3 The 2 SA system con 
sists of two types of enzymes: 2 SA synthetases and RNase L.4 
IFNs induce a family of 2 SA synthetase genes. The 2 SA syn 
thetases require double stranded RNA (dsRNA) for their activ 
ities. After activation by dsRNA which is frequently produced 
during viral infection, 2 SA synthetases convert ATP molecules 
to pyrophosphate (ppi) and a series of unique, 5' phosphory 
lated, 2' 5' linked oligoadenylates known as 2 SA with the gen 
era! formula ppp(A2'p5')nA (n ;;;, 2). 2 SA binds RNase L with 
high affinity, converting it from its inactive, monomeric state 
to a potent dimeric endoribonuclease, resulting in degradation 
of single stranded viral and cellular RNAs. The 2 SA system 
mediates host defence against certain types of viruses. The 
overexpression of RNase L in NIH 3T3 cellsmarkedly enhances
the antiviral function of IFN, whereas the dominant negative
RNase L suppresses the antiviral activity of IFN in SVT2 cells.5,6
Mice containing homozygous disruption of the RNase L gene
succumbs to encephalomyocarditis (EMCV) infection more
rapidly than infectedwild typemice.7 A broad range of viruses
including HIV 1, vaccinia virus, human parainfluenza virus 3,
vesicular stomatitis virus, and EMCV have shown to be inhib
ited in RNase L overexpressing cell lines.8
RNase L has been linked to apoptosis in response to viral
and non viral agents. RNase L null mice show enlarged thy
mus glands at early ages, suggesting that RNase L may be in
volved in T cell development. In situ assays for DNA
fragmentation on tissue sections from both the thymus and
spleen reveal a reduction in apoptosis in the untreated RNase
L / mice compared to the cognate wild typemice.7 The direct
activation of RNase L by introducing 2 5A into intact cells
leads to apoptosis, whereas a dominant negative RNase L de
creases the numbers of apoptotic cells generated by poliovi
rus infection, IFN and poly (I):poly (C) as well as
staurosporine treatments.9–11 A recent study revealed that
RNase L mediates virus induced apoptosis through activating
c Jun NH2 terminal kinase (JNK).
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The evidence has shown that RNase L plays a role in cancer
biology. The ARG462GLN variant of RNase L, which has an
attenuated enzymatic activity, is implicated in up to 13% of
prostate cancer cases. Individuals heterozygous for these
mutations exhibit a 150% increased risk of prostate cancer,
and homozygotes have greater than double of the risk, under
scoring the importance of inactivating RNase L in the etiology
of prostate cancer.13–16 The inhibitory effect of RNase L on tu
mour formation is believed to be due in part to its anti prolif
erative and pro apoptotic roles. However, no spontaneous
tumour formation has been observed in one year old RNase
L / mice. The effect of RNase L on tumourigenesis induced
by carcinogens is under investigation in our laboratory. Previ
ously we have reported that the overexpression of RNase L in
murine NIH 3T3 cells increased IFN anti proliferative func
tion.5 In this study, we have found that bonemarrow cells defi
cient in RNase L grew significantly faster compared to wild
type cells in response to granulate macrophage colony stimu
lating factor (GM CSF), suggesting that RNase L regulates cell
proliferation stimulated by other growth factors. To determine
the direct impact of RNase L on tumour growth in the absence
of IFN induced proteins, we have stably expressed RNase L in
P 57 cells, an aggressive mouse fibrosarcoma cell line. To as
sess the effect of RNase L expression on the ability of p 57 cells
to form tumours, these cells were implanted in athymic mice.
Results showed that tumour formation was significantly de
layed and the tumours grew much slower in the group with
RNase L (P RL) compared to the control group (P Vec). Our find
ings suggest that RNase L plays a critical role in the inhibition
of fibrosarcoma growth in nude mice.
Materials and methods
Cell culture
RNase L+/+ and / mouse embryonic fibroblasts (MEF), P 57
cells (a gift from Dr. Chaoqun Wu, Fudan University), were
grown in DMEM (The Media Lab of the Central Cell Service,
Cleveland Clinic Foundation) supplemented with 10% foetal
bovine serum (Biosource) and antibiotics in a humidified
atmosphere of 5% CO2 at 37 C. Mouse bone marrow cells iso
lated from RNase L+/+ and / mice were grown in RPMI 1640
supplemented with 10% foetal bovine serum and 10 ng/ml
murine GM CSF.
Overexpression of human RNase L in P-57 Cells
Murine fibrosarcoma cells (P 57) were transfected using Lipo
factamine reagent (Invitrogen), with a mammalian expres
sion vector, pcDNAneo (Invitrogen), inserted with or without
human RNase L cDNA. The cells were selected in the medium
containing G418 at 300 lg/ml. Twenty drug resistant clones
transfected with the human RNase L cDNA were isolated
and analysed for RNase L expression byWestern blot analysis.
The clonal cell lines containing the vector with RNase L insert
or an empty vector are referred to as P RL and P Vec,
respectively.
Western blot analysis
Cells were harvested by washing twice with ice cold phos
phate buffered saline (PBS) and collectedwith a scraper. Cyto
plasmic extracts were prepared by the suspension of cell
pellets in NP 40 lysis buffer (10 mM Tris HCl, pH 8.0, 5 mM
Mg(OAc)2, 90 mM KCl, 0.2 mM PMSF, 100 U/ml aprotinin,
10 lg/ml leupeptin and 2% NP 40). After centrifugation at
10,000g in a microcentrifuge at 4 C for 10 min, cell extracts
(100 lg per sample) were fractionated on SDS 10% polyacryl
amide gels and transferred to PVDF membranes (Millipore).
The membranes were blocked with 5% non fat milk in PBS
containing 0.02% sodium azide and 0.2% (v/v) Tween 20, and
incubated with a monoclonal antibody against human RNase
L for 1 h at room temperature. The membranes were then
washed with PBS containing 0.2% (v/v) Tween 20 and incu
bated with goat antimouse antibody conjugated with horse
radish peroxidase (Cell Signaling) for 1 h at room
temperature. After washing, RNase L was detected by a
chemiluminescence method according to the manufacturer’s
specification (Amersham).
Assay for cell proliferation
RNase L+/+ and / MEFs, P Vec and P RL cells (3 · 104) were
seeded in 6 well plates, and after 1 d, they were treated with
or without 1000 U/ml of murine IFN a (Biosource). Fresh IFN
was added again every other day. Viable cells were counted
by trypan blue dye exclusion assays daily. The proliferation
of RNase L+/+ and / bone marrow cells was determined
using the colorimetric CellTiter 96 aqueous Cell Proliferation
Assay according to the instruction provided by the manufac
turer (Promega). Briefly, cells (1 · 104 cells per well) were
grown in 96 wells plates in the presence of 10 ng murine
GM CSF. At various times of cell growth, 50 ll CellTiter 96
Aqueous reagent (40% v/v dilution in 1 · PBS) was added to
each well. Plates were incubated at 37 C for 2 h, and absor
bance was measured at 490 nm with a 96 well plate reader
(Spectra Max 340; Molecular Devices).
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rule out clonal variation as the cause of the anti tumour ef
fect, we separately implanted groups of four mice with two
other clones of P RL cells. The tumour results obtained from
the different clones of P RL cells (data not shown) were simi
lar to that from the first clone used for the experiment, thus
eliminating clonal differences as the basis for the anti tu
mour activity of RNase L.
Microscopically, the P Vec tumours demonstrated a uni
form herringbone growth pattern consisting of spindle
shaped cells that varied little in size and shape and had
scant cytoplasm with indistinct cell borders (Fig. 5a). Inter
estingly, dramatic differences in morphology were observed
in P RL tumours (Fig. 5b), which had a less distinct fascicular
or herringbone pattern. The tumour cells were epithelioid
with large round and polygonal cells, open chromatin, and
prominent central nucleoi. They also showed prominent
pleomorphism with variable cell shape and nuclear size. This
morphologic difference resembled that of the cultured cells
(Fig. 3a).
P-RL tumour growth is due to suppression of RNase L
expression
It was possible that P RL tumours started to grow eventually
in the nude mice were due to the suppression of RNase L
expression by an unknown mechanism. To determine RNase
L level in the tumour cells, RNase L in P RL tumours was mea
sured by Western blot analysis in tumour extracts using a
monoclonal antibody to human RNase L. As shown, the
expression of RNase L was completely shut down in the P
RL tumours, suggesting that RNase L plays an important role
in the inhibition of tumour growth (Fig. 6).
Discussion
RNase L has been suggested to function as a tumour suppres
sor based on its roles in mediating apoptosis and anti prolif
erative activity of IFN.18 Our findings provide the first direct
evidence that RNase L is able to inhibit tumour growth
Fig. 3 – Morphology of P-RL and P-Vec cells. Photographs of the unstained cells at different growth stage (a) and colonies
formed in soft agar were taken (b) under Olympus CK·31 at 100· magnification. LD: low density; HD: high density.
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produces an enhanced anti proliferative effect on MEFs,
RNase L is able to inhibit cell proliferation independent of
IFN (Fig. 1a). In addition, RNase L also regulates the growth
of bone marrow cells in the presence of GM CSF, suggesting
a broader role of RNase L in mediating cell proliferation
(Fig. 1b). Surprisingly, we found that the overexpression of
RNase L suppressed the tumour cell growth although there
was no significant difference between P RL and P Vec cells
in response to IFN (Fig. 2b). The expression of RNase L is cell
specific. The expression level of RNase L in certain cell types
such as B cells, lymphoblasts, myelobasts and monocytes is
about 20 30 fold higher than that in fibroblasts (our unpub
lished data). How these cells survive with the extremely high
level of RNase L remains to be investigated.
RNase L is believed to display its biological function
through regulating mRNA stability after IFN treatment. Ribo
somal and viral RNAs have been the first reported targets of
RNase L. Documented evidence has shown that RNase L plays
an important role in the stability of several gene products,
including IFN induced genes, such as ISG43, ISG1519 and
PKR20 in RNase L null cells; MyoD mRNA in myocytes21 and
mitochondrial mRNAs in H9 lymphocytes.22 However, in the
absence of viral infection, the sources of dsRNA and 2 5A to
activate 2 5A synthetase, and RNase L remain obscure. It is
possible that RNase L can indirectly regulate gene expression
through interacting with other proteins because RNase L con
tains structurally nine ankyrin repeats, a typical protein pro
tein interaction domain. Recently, Peltz’s group has
demonstrated that RNase L is indeed able to regulate gene
expression by interacting with another protein.23 They dis
covered that RNase L can interact with human translation ter
mination factor eRF3/GSPT1 to modulate the translation
termination process, resulting in regulating gene expression.
Their results outline a novel role for RNase L as a regulator of
translation.
The effect of RNase L on cell growth was not obvious when
cells were grown at a low density (Fig. 3a). However, when
cells grew at a high density, the morphological difference be
tween these two cell lines was dramatic. P Vec cells grew
more aggressively. Even though the cells have grown to con
fluence, P Vec cells continued to grow, and piled up to form
individual clones if fresh medium was provided. P RL cells
ceased growing after cells became confluent. These cells were
large and had a polygonal shape, probably due in part to the
altered cell morphology. Furthermore, anchorage indepen
dent growth in soft agar (Fig. 3b) is consistent with the obser
vation in tumour formation in nude mice (Fig. 4a). These
findings indicate a role of RNase L in suppressing tumour
growth. Surprisingly, no spontaneous tumour formation has
been observed in one year old RNase L / mice. Currently,
the effect of RNase on tumourigenesis induced by carcino
gens is under investigation in our laboratory. We are also
cross breeding RNase L / with P53 / mice to determine
whether P53 / mice deficient RNase L results in an increase
of spontaneous tumour formation.
The P Vec tumours showed typical fibrosarcoma histology
with fascicular, herringbone growth pattern and slender spin
dled cells. However, with the overexpression of RNase L, the
tumour cells demonstrated polymorphism with more epith
eloid cells. Since RNase L is involved in the regulating the acti
vation of the JNK pathway, which roles in the control of cell
motility and morphogenesis have been well established,24
overexpression of RNase L may affect JNK regulated cytoskel
etal molecules, and therefore cause the morphological alter
ation. Interestingly, increased single cell necrosis was
observed in P RL tumours. Whether the increased cell death
is due to the overexpression of RNase L promoting apoptosis
needs to be further investigated.9–11
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